Evaluation of a pre-co-seasonal and a perennial schedule of a single multiallergen depigmented-polymerized subcutaneous immunotherapy in paediatric patients.

Main Article Content

Ana Martinez-Cañavate Burgos
Javier Torres
Ana Belen Molina
Candelaria Muños
Manuel Diaz
Jose Luis Corzo
Luis Echeverria
Jaime Sanchez
Monica Ruiz-Garcia


Polyallergic, polysensitization, treatment schedules;, paediatrics, pollen allergy


Aim: Compare a pre-co-seasonal with a perennial schedule using an undiluted mixture of a depigmented-polymerized grass/Olea europaea immunotherapy (2,000 DPP/mL) in pediatric patients with rhinitis/rhinoconjunctivitis with or without controlled asthma.
Material and Methods: Primary objective was to determine the non-superiority of a perennial compared to a pre-co-seasonal schedule by means of Paediatric/Adolescent Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ/AdolRQLQ). Secondary objectives were Paediatric Asthma/Caregiver´s Quality of Life Questionnaire (PAQLQ/PACQLQ) Asthma Control Test (ACT), Visual Analogue Scale global assessment of allergic disease (VAS), use of resources and immunological response. All variables were compared during the pollen season (April-June) without (2015) and with (2016) immunotherapy.
Results: Forty patients were included in the study of which 29 patients were assigned to the perennial and 11 to the pre-co-seasonal schedule. During 2016 pollen season a significant improvement in the PRQLQ/AdolRQLQ, PAQLQ/AdolAQLQ, ACT and VAS score were observed both in perennial and pre-co-seasonal schedule group. No significant differences were seen between treatment schedules for PRQLQ/AdolRQLQ, PAQLQ/AdolAQLQ and ACT scores comparing both pollen seasons. A significant increase in sIgG4 and reduction in the number of rescue medications used and number of patients who needed visit to any specialist was observed in both treatment schedules during 2016 pollen season. No relevant differences were found in the safety profile of any treatment schedule.
Discussion: Treatment with undiluted mixture of a depigmented-polymerized Grass/Olea europaea allergen immunotherapy has proven to be effective both using a perennial and a pre-co-seasonal schedule and therefore suitable for polyallergic patients.

Abstract 89 | PDF Downloads 64 XML Downloads 1 HTML Downloads 4


1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63:S8–160.
2. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. https://doi.org/10.1016/j.jaci.2017.03.050
3. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: A longitudinal population-based study. Lancet. 2008;372:1049–1057. https://doi.org/10.1016/S0140-6736(08)61446-4
4. Dierick BJH, Van der Molen T, Flokstra-deBlok BMJ, Muraro A, Postma MJ, Kocks JWH, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and foodallergy. Exp Rev Pharmacoecon Outcomes Res. 2020;20(5):437–453. https://doi.org/10.1080/14737167.2020.1819793
5. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106:S12–S16. https://doi.org/10.1016/j.anai.2010.10.014
6. Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M, et al. Impact of rhinitis on work productivity: A systematic review. J Allergy Clin Immunol Pract. 2018;6(4):1274–1286.e9. https://doi.org/10.1016/j.jaip.2017.09.002
7. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth Van Wijk R, et al. EAACI guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798.
8. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–948. https://doi.org/10.1111/j.1398-9995.2007.01451.x
9. Klimek L, Brehler R, Hamelmann E, Kopp M, Ring J, Treudler R, et al. Evolution of subcutaneous allergen immunotherapy (part 1): From first developments to mechanism-driven therapy concepts. Allergo J Int. 2019;28:78–95. https://doi.org/10.1007/s40629-019-0092-4
10. Quercia O, Bruno ME, Compalati E, Falagiani P, Mistrello G, Stefanini GF. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: Comparison between two different treatment regimens. Eur Ann Allergy Clin Immunol. 2011;43(6):176–183.
11. Tworek D, Bochenska-Marciniak M, Kuprys-Lipinska I, Kupczyk M, KunaP. Perennial is more effective than pre-seasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis. Am J Rhinol Allergy. 2013;27:304–308. https://doi.org/10.2500/ajra.2013.27.3935
12. Pfaar O, Sager A, Robinson DS. Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: A retrospective study of 2927 paediatric patients. Pediatr Allergy Immunol. 2015;26(3):280–286. https://doi.org/10.1111/pai.12347
13. Mösges R, Valero Santiago A, Allekotte S, Jahed N, Astvatsatourov A, Sager A, et al. Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: A systematic review and meta-analysis. Clin Transl Allergy. 2019;9:29. https://doi.org/10.1186/s13601-019-0268-5
14. Alvarez-Cuesta E, Aragoneses-Gilsanz E, Martín-Garcia C, Berges-Gimeno P, Gonzalez-Mancebo E, Cuesta-Herranz J. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: Changes in quality of life. Clin Exp Allergy. 2005;35(5):572–578. https://doi.org/10.1111/j.1365-2222.2005.02245.x
15. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol. 1998;101(2 Pt1):163–170. https://doi.org/10.1016/S0091-6749(98)70380-X
16. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5(1):35–46. https://doi.org/10.1007/BF00435967
17. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(Suppl 82):1–20. https://doi.org/10.1111/j.1398-9995.2006.01219_1.x
18. Pfaar O, Biedermann T, Klimek L, Sager A, Robinson DS. Depigmented–polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitize patients. Allergy. 2013;68(10):1306–1313. https://doi.org/10.1111/all.12219
19. Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy. 2012;67(2):272–279. https://doi.org/10.1111/j.1398-9995.2011.02736.x
20. Cuesta-Herranz J, Laguna JJ, Mielgo R, Pérez-Camo I, Callejo AM, Begoña L, et al. Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA). Eur Ann Allergy Clin Immunol. 2019;51(5):222–233. https://doi.org/10.23822/EurAnnACI.1764-1489.104